At a glance
ClinicalIndex Comparison RecordN/ACompleted· 372 enrolled
Drug / intervention
Bausch & Lomb DVisc40 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD
In Brief
A clinical study evaluating Bausch & Lomb DVisc40 and Alcon VISCOAT® for Cataract. Completed, enrolled 372 participants across 1 site.
Detailed Summary
A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedApr 30, 2018
Enrollment StartMay 9, 2018
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.2 years ago
Interventions
Bausch & Lomb DVisc40device
Ophthalmic viscosurgical device
Alcon VISCOAT®device
Ophthalmic viscosurgical device